Wall Street Is Buying Phase 1 Again

On Friday, a biotech company with exactly one cohort of human data rang the opening bell at the Nasdaq. Lycia Therapeutics priced its IPO at $18.00 per share, watched it trade as high as $36.49 on Friday, and closed day one at $30.00 — a 67% pop. By Monday the underwriters had exercised their overallotment option in full, taking the total raise to $365.1 million against an original target of roughly $228 million. In Tuesday trading the stock sits near $26, which still values the company at about $1.5 billion.

What does $1.5 billion buy? A Phase 1 asset that has, so far, reported results from a single dose cohort of healthy volunteers.

That is not a knock on Lycia — the science is genuinely interesting, and we'll get to it. It's an observation about the market that just paid for it. Windows like this one don't announce themselves with a press release. They announce themselves with upsized order books and exercised greenshoes for preclinical-adjacent risk.

The Window Is Wide Open

Lycia is not an outlier. It is the latest datapoint in the most active year for biotech IPOs since the pandemic bubble.

By BioSpace's count, 31 biotechs had gone public in 2026 through late October — before Lycia made it 32. For context, the industry managed just 8 IPOs in all of 2025, 19 in 2024, 13 in 2023, and 17 in 2022. This year has quadrupled last year's total with two months still on the clock.

And the class of 2026 isn't just bigger — it's setting records:

• Kailera Therapeutics raised $625 million in April to fund obesity drugs licensed from China — at the time, the largest biotech IPO ever.
• Parabilis Medicines, a cancer-focused peptide drug developer, broke that record eight weeks later with a $670 million June debut — the biggest in biotech history.
• ADARx Pharmaceuticals raised $446 million in September, the year's third-largest.
• October alone has seen TRexBio, Retension Pharmaceuticals, City Therapeutics, and Iambic Therapeutics start trading, with Lycia closing out the month.

The pipeline behind them is still stacked: Windward Bio is moving toward a listing, and Aspen Neuroscience, Bambusa Therapeutics, and Rezera (the renamed NodThera) have all filed. The sector tape supports the enthusiasm — the SPDR S&P Biotech ETF (XBI) is up roughly 26% year to date, with the Nasdaq Biotechnology Index ETF (IBB) up about 25%.

Briefings like this are free to read with a free AlphaBriefing membership. Join free →

What $1.5 Billion of Phase 1 Looks Like

Lycia is a real company with a real scientific pedigree. It was founded on the work of Carolyn Bertozzi, the Stanford chemist who won the 2022 Nobel Prize in Chemistry. Her lab discovered LYTACs — lysosomal targeting chimeras — a class of molecules that can tag proteins floating outside cells and shuttle them into the cell's lysosome to be destroyed. That matters because the better-known protein degraders (PROTACs, molecular glues) only work on proteins inside cells. Extracellular targets — circulating antibodies, inflammatory signals — have largely been out of reach for degradation.

Lycia's lead program, LCA-0061, uses that machinery to degrade IgE, the antibody that drives allergic disease. The commercial logic is borrowed from an existing blockbuster: Xolair, the IgE-blocking antibody, was approved by the FDA for food allergy in 2024 and, per Lycia's prospectus, had been prescribed to more than 100,000 US food allergy patients by 2025, contributing to over $4 billion in US annual sales. The company cites projections that worldwide sales for food allergy treatments could grow beyond $15 billion over the coming decade. More than 33 million Americans have a food allergy. Lycia's pitch: don't just block IgE — eliminate it, deeper and longer, without Xolair's weight-based dosing constraints.

The early evidence: a single 70 mg subcutaneous dose in the first cohort of healthy atopic volunteers produced what the company describes as rapid, deep, and sustained reduction in total and free IgE. Behind it sit a fast-follower IgE program (LCA-0062, still preclinical) and a Graves' disease degrader (LCA-0321, in Phase 1). Every meaningful readout — the food allergy patient data, the Graves' data, the follow-on program's first results — lands in 2027.

So: a credible platform, a Nobel-laureate origin story, a proven commercial precedent, and no clinical catalyst for over a year. The float is thin — only about a third of the company's 57.7 million shares trade freely; the rest are locked up. And the market just marked it at $1.5 billion.

Which raises the question that actually matters for your money. Lycia is the latest marquee biotech IPO of 2026 to surge on debut. We now have six months of aftermarket data on what happened to the people who bought the earlier ones — and it tells you exactly where in this cycle you're standing.

A free membership gets you access to every free article at AlphaBriefing.com: Join AlphaBriefing

The rest of this briefing is free — it just requires a free AlphaBriefing account: the aftermarket scoreboard on 2026's three record IPOs (one is down 49% from its first-day close), the lockup and float math on Lycia including the April 2027 date that matters, and the four upcoming pricings that will signal when this window starts to close.

Create your free account → — 30 seconds, no card.